Showing results (251-260 of 395) with videos related to
Sort By:
Pageof 40
Science Translational Medicine|January 17, 2020
Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistanceEugene Park, Jingyu Chen, Andrew Moore, et al.Blood|May 27, 2016
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapyCarmen Diana Herling, Marion Klaumünzer, Cristiano Krings Rocha, et al.Science Immunology|July 30, 2017
Tumor-derived exosomes modulate PD-L1 expression in monocytesFranziska Haderk, Ralph Schulz, Murat Iskar, et al.Blood|June 30, 2023
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trialJohn F Seymour, John C Byrd, Paolo Ghia, et al.Blood|July 17, 2009
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemiaBarbara F Eichhorst, Raymonde Busch, Stephan Stilgenbauer, et al.Blood|April 27, 2019
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variablesAndrew W Roberts, Shuo Ma, Thomas J Kipps, et al.European Journal of Immunology|March 31, 2021
Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patientsIgor Kos, Benedikt Balensiefer, Vadim Lesan, et al.Blood|January 29, 2021
LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcomeLorenz Thurner, Natalie Fadle, Jörg Thomas Bittenbring, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.International Journal of Cancer|June 15, 2017
TP53 mutation and survival in aggressive B cell lymphomaThorsten Zenz, Markus Kreuz, Maxi Fuge, et al.Pageof 40